Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment. - Ahrens M; Haanen J; Albiges L; Goupil MG; Boleti E; Gravis G; Fléchon A; Grimm MO; Bedke J; Barthélémy P; Castellano D; Mellado B; et al. (Cancer treatment and research communications, 2026)